- Home
- CTOR vs KPTI Comparison
CTOR vs KPTI Comparison
Compare CTOR & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- KPTI
- Stock Information
- Founded
- CTOR 2021
- KPTI 2008
- Country
- CTOR United States
- KPTI United States
- Employees
- CTOR N/A
- KPTI N/A
- Industry
- CTOR
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- KPTI Health Care
- Exchange
- CTOR NYSE
- KPTI Nasdaq
- Market Cap
- CTOR 63.7M
- KPTI 44.5M
- IPO Year
- CTOR N/A
- KPTI 2013
- Fundamental
- Price
- CTOR $4.35
- KPTI $4.66
- Analyst Decision
- CTOR Buy
- KPTI Buy
- Analyst Count
- CTOR 2
- KPTI 6
- Target Price
- CTOR $6.00
- KPTI $48.50
- AVG Volume (30 Days)
- CTOR 3.3M
- KPTI 49.5K
- Earning Date
- CTOR 08-11-2025
- KPTI 08-05-2025
- Dividend Yield
- CTOR N/A
- KPTI N/A
- EPS Growth
- CTOR N/A
- KPTI N/A
- EPS
- CTOR N/A
- KPTI N/A
- Revenue
- CTOR N/A
- KPTI $142,126,000.00
- Revenue This Year
- CTOR N/A
- KPTI $2.09
- Revenue Next Year
- CTOR N/A
- KPTI $12.90
- P/E Ratio
- CTOR N/A
- KPTI N/A
- Revenue Growth
- CTOR N/A
- KPTI 1.19
- 52 Week Low
- CTOR $0.55
- KPTI $3.51
- 52 Week High
- CTOR $49.00
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- KPTI 52.67
- Support Level
- CTOR N/A
- KPTI $4.23
- Resistance Level
- CTOR N/A
- KPTI $4.80
- Average True Range (ATR)
- CTOR 0.00
- KPTI 0.33
- MACD
- CTOR 0.00
- KPTI 0.05
- Stochastic Oscillator
- CTOR 0.00
- KPTI 73.97
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.